Search clinical trials for: Gemcitabine / Cisplatin / Sorafenib

Total 6399 results

Technische Universität Dresden
Bayer

Completed

Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age (SORAML)

Acute Myeloid Leukemia (AML)

Germany
University Hospital, Geneva
Bayer

Completed

Sorafenib in Newly Diagnosed High Grade Glioma

Glioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

Switzerland
Damanhour University
Mransoura University

Completed

Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.

Hepatocellular Carcinoma

Egypt
Zhejiang University

Unknown

Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation (HCC)

HCC

China
Southwest Hospital, China
Xijing Hospital; Xiangya Hospital of Central South University; Henan Cancer Hospital and other collaborators

Unknown

Combined Treatment of RFA and Sorafenib on Recurrent HCC (REPEAT)

HCC | Radiofrequency Ablation | Sorafenib

China
Stanford University

Completed

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Kidney Cancer | Carcinoma, Renal Cell | Kidney Disease

United States
Samsung Medical Center

Completed

Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Korea, Republic of
Fudan University

Terminated

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Leiden University Medical Center

Completed

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Thyroid Cancer

Netherlands
University of Pennsylvania

Completed

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Metastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid Cancer

United States
Far Eastern Memorial Hospital

Unknown

A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Taiwan
Mohammed Milhem
University of Iowa; Holden Comprehensive Cancer Center

Completed

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Sarcoma | Pancreatic Ductal Adenocarcinoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Bladder Cancer | Urethral Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Royal Marsden NHS Foundation Trust

Completed

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Non-Hodgkins Lymphoma

United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Unspecified Adult Solid Tumor, Protocol Specific | Localized Gallbladder Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Gallbladder

United States
Bayer

Completed

Relative Bioavailability of Sorafenib Tablet for Oral Suspension

Biological Availability

Germany
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
First Affiliated Hospital of Fujian Medical University

Recruiting

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Biliary Tract Malignancies

China
Ruijin Hospital

Not yet recruiting

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma

China
Center Eugene Marquis

Completed

Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma (MispheC)

Cholangiocarcinoma

France
University of Zurich

Completed

Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy

Cholangiocellular Carcinoma

Switzerland
AstraZeneca

Unknown

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Drug/Agent Toxicity by Tissue/Organ

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
Eli Lilly and Company
Aventis Pharmaceuticals

Completed

A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Italy
Bayer

Completed

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety (SORINT)

Carcinoma, Hepatocellular

Germany
Bayer

Completed

Regulatory Post Marketing Surveillance Study on Nexavar®

Carcinoma, Renal Cell | Carcinoma, Hepatocellular

Korea, Republic of
Bayer

Completed

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Carcinoma, Hepatocellular

Japan
Bayer

Completed

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Belgium, Italy, Spain, Germany, France, Netherlands, Switzerland, Poland, Sweden, United Kingdom, Denmark
Bayer

Terminated

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Carcinoma, Renal Cell

United States
Bayer

Completed

INSIGHT - Post Marketing Surveillance (INSIGHT)

Carcinoma, Hepatocellular

Germany, Austria
Bayer

Completed

Sorafenib Gastric Cancer Asian Phase I Study

Gastric Cancer

Japan
Bayer
Amgen

Completed

Sorafenib/Docetaxel Dose Escalation Trial

Neoplasms

United States
Beijing Shenogen Biomedical Co., Ltd
The First Affiliated Hospital with Nanjing Medical University; General Hospital... and other collaborators

Terminated

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Hepatocellular Carcinoma (HCC)

China
University of Wisconsin, Madison
Bayer

Completed

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Carcinoma, Non Small Cell Lung

United States
Bayer

Completed

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Carcinoma, Renal Cell

Japan
Bayer

Completed

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China (SUCCESS)

Carcinoma, Hepatocellular

China
Bayer

Completed

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting (NEXST)

Carcinoma, Renal Cell

Poland
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma (SARAH)

Liver Carcinoma

France
Massachusetts General Hospital
Bayer; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

Hepatocellular Carcinoma

Taiwan, Hong Kong, China, Thailand, Korea, Republic of, Singapore, Japan
Bayer

Completed

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Canada
Bayer
Amgen

Completed

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Cancer | Carcinoma, Non-Small Cell Lung

United States, Germany
Chinese Society of Lung Cancer

Completed

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Non-Small Cell Lung Cancer

China
Medical Research Council

Completed

Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

Kidney Cancer

United Kingdom
Bayer

Completed

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Poland, China, Slovakia, France, Germany, Indonesia, Korea, Republic of, Sweden, Philippines, Austria, Colombia, Czech Republic, Mexico, Russian Federation, Slovenia, Argentina, Greece, Netherlands
Istituto Clinico Humanitas

Completed

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

Sarcoma, Soft Tissue

Italy
Bayer

Active, not recruiting

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (JPMS-DTC)

Thyroid Carcinoma

Japan
Bayer
ICON Clinical Research

Completed

Sorafenib Long Term Extension Program (STEP)

Neoplasms

Spain, Hong Kong, Canada, Germany, France, United States, United Kingdom, Taiwan, New Zealand, Australia, Belgium, China, Bulgaria, Italy, Colombia, Poland, Korea, Republic of, Brazil, Ukraine

Search clinical trials for: Gemcitabine / Cisplatin / Sorafenib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations